DS-6000a
medsir,Daiichi Sankyo
['rcc,(-irccs),(-srcc),(-urcc)', 'ovarian', 'medsir']
last day of #asco22! great talk by on first-in-human study of ds-6000a in advanced rcc and ovarian tumors:
- well tolerated
- early clinical signals in heavily pretreated pts with advanced platinum-resistant ovarian tumors and rcc
#rcc #ovariancancer #kidneycancer 
Bring your idea to life?? 
Creating successful IITs & optimizing drug development ?? 
Medica Scientia Innovation Research
 ????&????
https://t.co/yp3O5Lylqc